Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2: randomized clinical trial COVID-19

VALL HEBRON UNIVERSITY HOSPITA0 个研究点目标入组 117 人开始时间: 2020年5月5日最近更新: 2020年9月28日

适应症

试验速览

暂无简介。

•Age = 18 years.
•Patients with at least 5 days of PN.
•Baseline liver parameters before PN: GGT, alkaline phosphatase < 100 U/dL and direct bilirubin <1.2 mg/dL al inicio de NP.
•Liver parameter alterations: GGT = 300 U/dL, alkaline phosphatase = 200 U/dL or direct bilirubin =1.8 mg/dL
•Forseeing to receive at least 5 days of PN.
•Admitted in the ICU of the Valle Hebron University Hospital
•Willing to give their IC in writing for the trial and be able to do so.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 117
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 117

•- Lipids administration contraindicated
•- Have a history of hypersensitivity of idiosincratic reactions to any component of intravenous lipid emulsions.
•- Home parenteral nutrition patients
•- Liver transplantation
•- Liver parameters alterations before PN: 20% above upper normal values.
•- Patients rejection to participate.

发起方

VALL HEBRON UNIVERSITY HOSPITA